<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000367460"><TermName>nelarabine</TermName><TermPronunciation>(neh-LAR-uh-been)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat certain types of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL). It belongs to the family of drugs called antimetabolites. Also called 506U78 and Arranon.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000711218" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;nelarabine&quot;" language="en" id="_3"/><MediaLink ref="CDR0000711219" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;nelarabina&quot;" language="es" id="_4"/><SpanishTermName>nelarabina</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento usado para tratar ciertos tipos de leucemia linfoblástica aguda de células T (LLA-T) y linfoma linfoblástico de células T (LLB-T). Es un tipo de antimetabolito. También se llama 506U78 y Arranon.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2004-04-23</DateFirstPublished><DateLastModified>2006-09-08</DateLastModified><RelatedInformation><RelatedDrugSummaryRef href="CDR0000492016">Nelarabine</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
